Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II Trial of SENS-401 for the Treatment of Sudden Sensorineural Hearing Loss (or SSNHL) in Pediatric Population

Trial Profile

A Phase II Trial of SENS-401 for the Treatment of Sudden Sensorineural Hearing Loss (or SSNHL) in Pediatric Population

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 28 Jun 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Arazasetron (Primary)
  • Indications Sensorineural hearing loss
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Sensorion
  • Most Recent Events

    • 28 Jun 2019 According to a Sensorion media release, the company intend to continue discussions and propose this phase 2 clinical trial protocol in order to investigate SENS-401 for the treatment of severe hearing loss (SSNHL).
    • 28 Jun 2019 According to a Sensorion media release, the European Medicines Agency (EMA) has accepted its Pediatric Investigation Plan (PIP) for both development in the treatment of severe hearing loss (SSNHL) and for prevention of ototoxicity caused by cisplatin (CIO) in the pediatric population.
    • 29 Jun 2018 According to a Sensorion media release, This trial is expected to begin in the coming weeks.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top